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Small airway epithelial-C/EBPβ is increased
in patients with advanced COPD
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Abstract
The expression of CCAAT/enhancer-binding protein (C/EBP)β in the small airway epithelium of COPD is unknown.
C/EBPβ was assessed in peripheral lung tissue of non-smoking/smoking controls and patients with GOLD I-IV COPD
by quantitative immunohistochemistry. The expression of C/EBPβ was decreased in smokers compared to never
smokers. Furthermore, C/EBPβ was significantly elevated in advanced COPD vs. asymptomatic smokers, and the
expression correlated to lung function decline. As C/EBPβ exerts pro-inflammatory effects in the context of cigarette
smoke, the elevated C/EBPβ in advanced COPD may be an indication of a breakdown of regulatory mechanisms
and excessive inflammation.
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Findings
Chronic obstructive pulmonary disease (COPD) is char-
acterized by small airway inflammation. While glucocor-
ticoids (GCs) and β2 agonists are mainstay in the
management of COPD, these classes of drugs are, by
and large, ineffective in preventing disease progression
[1]. The lack of efficient pharmaceutical options is in
part due to the incomplete understanding of the intri-
cate molecular mechanisms contributing to the disease.
The transcription factor CCAAT/enhancer binding pro-
tein (C/EBP)β regulates inflammatory [2] and host defense
genes [3] in the airway epithelium. Lung epithelial-C/
EBPβ activates the inflammatory response to cigarette
smoke [4], as well as lipopolysaccharide (LPS) [3]. Sup-
pression of LPS-induced airway inflammation by β2 ago-
nists is, however, also mediated by lung epithelial-C/EBPβ
[3]. In addition, glucocorticoids increase the expression
and transcriptional activity of C/EBPβ. Transactivation by
glucocorticoids has in contrast to pro-inflammatory
stimuli been suggested to up-regulate host defense
genes [5, 6]. Hence, cigarette smoke and microbial ligands,
as well as GCs and β2 agonists may all activate airway-
epithelial C/EBPβ in COPD, with the possibility of
different outcomes depending on the stimuli. There is cur-
rently insufficient knowledge of the expression of C/EBPβ
in the small airways of COPD, in particular in end-stage
disease where GC/β2 agonist therapy is mainstay.
We obtained peripheral tissue specimens from patients
with stable GOLD I-IV COPD (n = 30), as well as con-
trols with or without a smoking history (n = 14) (Table 1).
The study was approved by the Swedish Research Ethics
Committee in Lund, Sweden. All study subjects signed
informed consent to participate. Formalin-fixed and
paraffin-embedded tissue sections were pre-treated with
a pH 6.1 buffer (EnVision™ FLEX Target Retrieval Solution,
Dako, Glostrup, Denmark). The expression of C/EBPβ was
visualized by immunohistochemistry using a polyclonal
rabbit anti-C/EBPβ antibody (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), and EnVision™ Peroxidase/
DAB Detection System kit on an Autostainer Plus
(DakoCytomation, Glostrup). Automated immunohis-
tochemistry allowed for minimized operator error be-
tween tissue samples.
C/EBPβ is decreased in the small airway epithelium of
asymptomatic smokers
Strong immunoreactivity to C/EBPβ was observed in the
peripheral airway epithelium, as well as in alveolar mac-
rophages of COPD patients and asymptomatic controls
(Fig. 1a-c). C/EBPβ positive cells were furthermore iden-
tified within and in the epithelial interface of lymphoid
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follicles [7], in lung tissue collected from patients with
COPD (inlet of Fig. 1c).
An Aperio ScanScope Slide Scanner (Aperio Tech-
nologies, Vista, CA) was used to generate digital images
of the tissue sections, and morphometric analyses were
performed using Aperio ImageScope v.10.0 software
(Aperio Technologies) [8]. Computerized image analysis
revealed that the expression of C/EBPβ was significantly
lower in the airway epithelium among asymptomatic
controls with a smoking history compared to never
Table 1 Baseline demographics and clinical characteristics
Parameter Never smokers Smokers w/o COPD GOLD I-II COPDb GOLD III-IV COPDc p ANOVA
Subjects (n)a 8 6 18 12
Gender (female/male) 6/2 3/3 5/13 6/6
Age (years) 63 ± 4.8 56 ± 3.2 68 ± 1.8 61 ± 1.2 <0.05
Height (m) 1,64 ± 0.033 1.72 ± 0.05 1,74 ± 0.02 1,7 ± 0.031 ns
Weight (kg) 64,6 ± 4.6 69.2 ± 4.4 73,1 ± 3.5 67,7 ± 4.1 ns
Body mass index 23,9 ± 1.3 23.3 ± 1.1 24,4 ± 1.1 23,3 ± 0.94 ns
Pack years N/A 43 ± 9.7 45 ± 3.5 41 ± 3.2 ns
Smoker/ex-smoker N/A 3/3 7/11 0/12
FEV1/FVC 85,9 ± 5.7 77.8 ± 2.4 61,4 ± 1.9 33,4 ± 2.1 <0.001
FEV1 (% of predicted) 109,8 ± 6.2 93.8 ± 4.2 74,1 ± 2.7 26,2 ± 2.7 <0.001
Corticosteroids (yes/no/unknown) 0/8/0 0/6/0 2/16/0 9/2/1
Bronchodialator (yes/no/unknown) 0/8/0 0/6/0 6/12/0 9/2/1
aAll surgeries were performed at Skåne University Hospital, in Lund, Sweden
bTissue samples were obtained during lung resection surgery for bronchial tumour
cTissue samples were obtained from GOLD II COPD patients during lung resection surgery for bronchial tumour, and from GOLD IV COPD patients during
lung transplantation
Fig. 1 Reduced expression of C/EBPβ in asymptomatic smokers and elevated expression in advanced COPD. Light micrographs of the immunoreactivity
to CCAAT/enhancer-binding protein (C/EBP)β in peripheral pulmonary tissue of a (a) never-smoker, (b) asymptomatic smoker, and (c) patient with very
severe chronic obstructive pulmonary disease (COPD). Immunoreactivity was detected by DAB (brown). Sections were counterstained with
Mayer’s Hematoxylin (blue). Scale bar indicates 100 μm. The epithelium (Ep) is denoted and an arrowhead indicates a positive cell in (a).
Inlet of (c) shows immunoreactivity to C/EBPβ in a tertiary lymphoid follicle. d Immunoreactivity (defined as number of positive pixels/mm2) to C/EBPβ
in peripheral lung epithelium of never-smokers, asymptomatic smokers and patients with mild-moderate (global initiative of COPD, GOLD I-II) and
severe-very severe (GOLD III-IV) COPD. Horizontal lines indicate mean value. e Pearson correlation coefficient analysis of the immunoreactivity/mm2 to
C/EBPβ in peripheral lung epithelium and the forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) of smokers without COPD and
patients with GOLD I-IV COPD. Clear circles: never smokers without airway obstruction; grey circles: asymptomatic smokers, triangles: GOLD I-II COPD;
squares: GOLD III-IV COPD. n = 6-18. *p < 0.05
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smokers (p < 0.05, Fig. 1d). The lower expression of C/
EBPβ was associated with a reduced immunoreactivity
to the Marker of Proliferation (M) KI67 (rabbit poly-
clonal antibody A0047, DakoCytomation) suggestive of
an attenuated proliferation of the airway epithelium
(0.02 ± 0.004 vs. 0.0082 ± 0.0026; mean ± SEM, p < 0.01).
The reduced expression of C/EBPβ corroborates our
previous finding of significantly decreased CEBPB mRNA
in the bronchial epithelium of current and former
smokers, compared to never smokers [4], and reduction
of CEBPB mRNA and C/EBPβ protein in bronchial epi-
thelial cells stimulated with cigarette smoke extract
in vitro [4]. Thus, C/EBPβ is down-regulated by cigarette
smoke in both the proximal and distal airway epithelium.
This may be part of a compensatory mechanism of feed
back inhibition, as an adaptive attempt to control chronic
inflammation. C/EBPβ contributes to the differentiation of
the airway epithelium during organogenesis, and pro-
motes club cell differentiation at the expense of goblet cell
differentiation [9]. As cigarette smoke stimulates goblet
cell differentiation in vitro [10], decreased expression of
C/EBPβ in the distal airways may thus provide a mechan-
istic explanation for goblet cell hyperplasia induced by
cigarette smoke. While the smokers included in our study
were asymptomatic, decreased C/EBPβ may over time
lead to clinical presentation with mucus hypersecretion.
In support of this, the activity of C/EBPβ in the bronchial
epithelium is decreased in smokers with chronic bron-
chitis [11], compared to asymptomatic smokers.
Airway epithelial-C/EBPβ is elevated in advanced COPD
The expression of airway epithelial-C/EBPβ was signifi-
cantly increased in advanced (GOLD III-IV) COPD,
compared to asymptomatic smokers (p < 0.05, Fig. 1d).
Furthermore, a negative correlation between lung func-
tion and the airway expression of C/EBPβ was observed
(r = −0.35 p < 0.05, Fig. 1e), suggesting a role for C/EBPβ
in disease progression. The expression of the lung-
enriched C/EBPα, which cooperates with C/EBPβ in
various cellular functions [2], was not significantly differ-
ent in any of the groups within the cohort (C/EBPα
rabbit polyclonal antibody (14AA) sc-61, Santa Cruz
Biotechnology, Dallas, TX, USA; data not shown).
Mechanistically, it is possible that the elevation of C/
EBPβ represents a breakdown of the suggested feed back
inhibition observed in cigarette smoke-induced inflamma-
tion, leading to escalating inflammatory processes in end-
stage COPD. Alternatively, chronic bacterial colonization
among COPD patients [12] may activate C/EBPβ. It is,
however, also possible that steroid and β2 agonist treat-
ment effected the expression of C/EBPβ in our study, as
airway epithelial-C/EBPβ is induced/activated by GCs
and β2 agonists [3, 6]. This may represent a novel
mechanism by which GCs and β2 agonists modulate
the transcriptional profile of the airway epithelium in ad-
vanced COPD. Future studies should address whether the
elevation of C/EBPβ is disease- or treatment-specific, and
if GCs and β2 agonists induces C/EBPβ to promote host-
defenses and act anti-inflammatory, or pro-inflammatory.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MM, LB, JSE, MRS and ABR conceived of and designed the study. MM and
ABR performed experiments. MM, JSE, MRS and ABR analyzed and
interpreted data. MSR and ABR wrote the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
We would like to thank Britt-Marie Nilsson and Karin Jansner at Lund University,
and Joanna Kasinska and Marie Bailey at McMaster University for technical
support and skillful assistance.
Author details
1Department of Experimental Medical Science, Lund University, Lund,
Sweden. 2Department of Respiratory Medicine and Allergology, Lund
University, Lund, Sweden. 3Department of Pathology and Molecular
Medicine, McMaster University, MDCL 4084, 1280 Main Street West, Hamilton,
ONL8S 4P1Canada. 4Department of Medicine, Firestone Institute of
Respiratory Health at St. Joseph’s Health Care, Hamilton, ON, Canada.
Received: 21 April 2015 Accepted: 22 October 2015
References
1. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al.
Global Strategy for the Diagnosis, Management, and Prevention of Chronic
Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2013;187:347–65.
2. Cassel TN, Nord M. C/EBP transcription factors in the lung epithelium. Am J
Physiol Lung Cell Mol Physiol. 2003;285:L773–781.
3. Roos AB, Barton JL, Miller-Larsson A, Dahlberg B, Berg T, Didon L, et al. Lung
epithelial-C/EBPbeta contributes to LPS-induced inflammation and its
suppression by formoterol. Biochem Biophys Res Commun. 2012;423:134–9.
4. Didon L, Barton JL, Roos AB, Gaschler GJ, Bauer CM, Berg T, et al. Lung
epithelial CCAAT/enhancer-binding protein-beta is necessary for the
integrity of inflammatory responses to cigarette smoke. Am J Respir Crit
Care Med. 2011;184:233–42.
5. Zhang N, Truong-Tran QA, Tancowny B, Harris KE, Schleimer RP. Glucocorticoids
Enhance or Spare Innate Immunity: Effects in Airway Epithelium Are Mediated
by CCAAT/Enhancer Binding Proteins. J Immunol. 2007;179:578–89.
6. Berg T, Cassel TN, Schwarze PE, Nord M. Glucocorticoids regulate the CCSP
and CYP2B1 promoters via C/EBPbeta and delta in lung cells.
Biochem Biophys Res Commun. 2002;293:907–12.
7. Mori M, Andersson CK, Svedberg KA, Glader P, Bergqvist A, Shikhagaie M,
et al. Appearance of remodelled and dendritic cell-rich alveolar-lymphoid
interfaces provides a structural basis for increased alveolar antigen uptake in
chronic obstructive pulmonary disease. Thorax. 2013;68:521–31.
8. Roos AB, Mori M, Gronneberg R, Osterlund C, Claesson HE, Wahlstrom J, et al.
Elevated exhaled nitric oxide in allergen-provoked asthma is associated with
airway epithelial iNOS. PLoS One. 2014;9:e90018.
9. Roos AB, Berg T, Barton JL, Didon L, Nord M. Airway epithelial cell differentiation
during lung organogenesis requires C/EBPalpha and C/EBPbeta. Dev Dyn.
2012;241:911–23.
10. Haswell LE, Hewitt K, Thorne D, Richter A, Gaça MD. Cigarette smoke total
particulate matter increases mucous secreting cell numbers in vitro: A
potential model of goblet cell hyperplasia. Toxicol In Vitro. 2010;24:981–7.
11. Didon L, Qvarfordt I, Andersson O, Nord M, Riise GC. Decreased CCAAT/
Enhancer Binding Protein Transcription Factor Activity in Chronic Bronchitis
and COPD. Chest. 2005;127:1341–6.
12. Murphy TF, Brauer AL, Schiffmacher AT, Sethi S. Persistent colonization by
Haemophilus influenzae in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med. 2004;170:266–72.
Mori et al. Respiratory Research  (2015) 16:133 Page 3 of 3
